Skip to main content
SpringerLink
Log in

PET and PET/CT Imaging in Testicular and Gynecologic Cancers

  • Chapter
Positron Emission Tomography

  • 2306 Accesses

Conclusions

In testicular cancer, PET is particularly useful for detection of viable tumor in posttreatment residual masses and for localization of marker-positive relapse. In both testicular and gynecologic cancer, PET can also be used to identify primary tumors and metastatic disease, and it can be used in surveillance for tumor recurrence. Investigations regarding the role of PET in these tumors have been increasing, but larger studies are needed to define the role of PET in the staging of cancer of the testis and ovary and in the evaluation of cancer of the cervix.

The role of FDG-PET is likely to be extended with the use of integrated PET/CT to assist in localizing disease with a view to guide biopsy. Further assessment of its role in determining and predicting response to treatment may have direct effects and benefits for individual patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mead GM. Testis. In: Price P, Sikora K, editors. Treatment of Cancer, 3rd ed. Chapman & Hall, London, 1995:627–645.

    Google Scholar 

  2. Dearnley DP, Huddart RA, Horwich A. Managing testicular cancer. Br Med J 2001;322:1583–1588.

    Article  Google Scholar 

  3. Wishnow KI, Johnson DE, Swanson, et al. Identifying patients at low risk clinical stage I testicular tumoirs who should be treated by surveillance. Urology 1989;34:339–343.

    Article  PubMed  CAS  Google Scholar 

  4. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for Stage I testicular teratoma. J Clin Oncol 1992;10:1762–1768.

    PubMed  CAS  Google Scholar 

  5. Horwich A. Testicular cancer. In: Horwich A, editor. Oncology: A Multidisciplinary Textbook. London: Chapman & Hall 1995:485–498.

    Google Scholar 

  6. Cullen MH. Adjuvant chemotherapy in high risk stage I non-seminomatous germ cell tumours of the testis. In: Horwich A, editor. Testicular Cancer: Investigation and Management. London: Chapman & Hall 1996:181–191.

    Google Scholar 

  7. Huddart R, Norman A, Shahidi M, et al. cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003;21;1513–1523.

    Article  PubMed  CAS  Google Scholar 

  8. Warde P, Jewett MA. Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin N Am 1998;25:425–433.

    Article  CAS  Google Scholar 

  9. McLeod DG, Weiss RB, Stablein DM, et al. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 1991;145:1178–1183.

    PubMed  CAS  Google Scholar 

  10. Fernandez EB, Moul JW, Foley JP, Colon E, McLeod DG. Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage I nonseminomatous germ cell tumours. Urology 1994;44:548–552.

    Article  PubMed  CAS  Google Scholar 

  11. Hain SF, O’Doherty MJ, Timothy, et al. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000;27:590–594.

    Article  PubMed  CAS  Google Scholar 

  12. Tsatalpas P, Beuthien-Baumann B, Kropp J, et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 2002;68:157–163.

    Article  PubMed  Google Scholar 

  13. Cremerius U, Wildberger JE, Borchers H, et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results in 50 patients. Urology 1999;54:900–904.

    Article  PubMed  CAS  Google Scholar 

  14. Albers P, bender H, Yilmaz H, et al. Positron emission tomography in the clinical staging of patients with stageI and II testicular germ cell tumours. Urology 1999;53:808–811.

    Article  PubMed  CAS  Google Scholar 

  15. Lassen U, Daugaard G, Eigtved A, et al. Whole body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003;30:396–402.

    Article  PubMed  CAS  Google Scholar 

  16. Mostofi FK, Spaander P, Grigor K, Parkinson CM, Skakkekaek NE, Oliver RTD. Consensus on pathological classifications of testicular tumours. In: Prostate Cancer and Testicular Cancer. EORTC Genitourinary Group Monograph 7. New York: Wiley-Liss, 1990:267–277.

    Google Scholar 

  17. Javadpour N. Current status of tumor markers in testicular cancer. A practical review. Eur Urol 1992;21:34–36.

    PubMed  Google Scholar 

  18. Kalofonos HP, Kosmas C, Pawlikowska TR, Bamias A, Snook D, Dhokia B, et al. Immunolocalisation of testicular tumours using radiolabelled monoclonal antibody to placental alkaline phosphatase. J Nucl Med Allied Sci 1990;34:294–298.

    PubMed  CAS  Google Scholar 

  19. Warren GP. Gallium scans in the evaluation of residual masses after chemotherapy for seminoma. J Clin Oncol 1995;13:2784–2788.

    PubMed  CAS  Google Scholar 

  20. Uchiyama M, Kantoff PW, Kaplan WD. Gallium-67 citrate imaging extragonadal and gonadal seminomas: relationship to radiologic findings. J Nucl Med 1994;35:1624–1630.

    PubMed  CAS  Google Scholar 

  21. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography of residual radiological abnormalities in postchemotherapy germ cell tumour patients. J Clin Oncol 1996;14:1637–1641.

    PubMed  CAS  Google Scholar 

  22. Hain SF, O’Doherty MJ, Timothy AR, et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000;83:863–869.

    Article  PubMed  CAS  Google Scholar 

  23. Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenkneckt GG, et al. FDG PET for detection and therapy control of metastatic germ cell tumour. J Nucl Med 1998;39:815–822.

    PubMed  CAS  Google Scholar 

  24. Sugawara Y, Zasadny KR, Grossman HB, et al. Germ cell tumour: differentiation of viable tumor, mature teratoma and necrotic tissue with FDG PET and kinetic modelling. Radiology 1999;211:249–256.

    PubMed  CAS  Google Scholar 

  25. Duchesne GM, Stenning SP, Aass N, Mead GM, Fossa SD, Oliver RTD. Minimal benefit from radiotherapy after chemotherapy for metastatic seminoma: analysis of Medical Research Council (MRCUK) database. Proc ASCO 1997;16:318.

    Google Scholar 

  26. De Santis M, Becherer A, Bokemeyer C, et al. 2-18Fluoro-2-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004;22:1034–1039.

    Article  PubMed  Google Scholar 

  27. Lodge MA, Lucas JD, Marsden PK, et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22–30.

    Article  PubMed  CAS  Google Scholar 

  28. Boerner AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226–230.

    Article  PubMed  CAS  Google Scholar 

  29. Rathmall AJ, Brand IR, Carey BM, Jones WG. Early detection of relapse after treatment for metastatic germ cell tumour of the testis: an exercise in medical audit. Clin Oncol R Coll Radiol 1993;5:34–38.

    Google Scholar 

  30. Coogan CL, Foster RS, Rowland RG, et al. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone. Urology 1997;50:957–962.

    Article  PubMed  CAS  Google Scholar 

  31. Mikhaeel NG, Timothy AR, O’Doherty MJ, Hain S, et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin’s lymphoma: comparison with CT. Leuk Lymphoma 2000;39:543–553.

    PubMed  CAS  Google Scholar 

  32. Schelling M, Avril N, Nahrig J, Kuhn W, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689–1695.

    PubMed  CAS  Google Scholar 

  33. Smith IC, Welch AE, Hutcheon AW, Miller ID, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676–1688.

    PubMed  CAS  Google Scholar 

  34. Bokemeyer C, Kollmannsberger C, Oechsle K, Dohmen BM, et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer 2002;86:506–511.

    Article  PubMed  CAS  Google Scholar 

  35. Parkin DM, Laara E, Muir CS. Estimates of worldwide frequency of sixteen major cancers in 1990. Int J Cancer 1998;80:827–841.

    Article  Google Scholar 

  36. FIGO Committee on Gynaecological Oncology: Benedet JL, Bender H, Jones H III, Ngan HYS, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynecol Obstet 2000;70:209–262.

    Article  CAS  Google Scholar 

  37. Kjorstad KE, Kolbenstvedt A, Strickert T. The value of complete lymphadenectomy in radical treatment of cancer of the cervix, stage IB. Cancer (Phila) 1984;54:2215–2219.

    Article  PubMed  CAS  Google Scholar 

  38. Alvarez RD, Potter ME, Soong SJ, Gay FL, Hatch KD, Partridge EE, Shingleton HM. Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients. Gynecol Oncol 1991;43:108–112.

    Article  PubMed  CAS  Google Scholar 

  39. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:352–357.

    Article  PubMed  CAS  Google Scholar 

  40. Steren A, Nguyen HN, Averette HE, Estape R, Angioli R, Donato DM, et al. Radical hysterectomy for stage IB adenocarcinoma of the cervix: the University of Miami experience. Gynecol Oncol 1993;48:355–359.

    Article  PubMed  CAS  Google Scholar 

  41. Piver MS, Barlow JJ. Para-aortic lymphadenectomy, aortic node biopsy, and aortic lymphangiography in staging patients with advanced cervical cancer. Cancer (Phila)1973;32:367–370.

    Article  PubMed  CAS  Google Scholar 

  42. Brown C, Buchsbaum HJ, Tewfik HH, et al. Accuracy of lymphangiography in the diagnosis of paraaortic lymph node metastases from carcinoma of the cervix. Obstet Gynecol 1979;54:571–575.

    PubMed  CAS  Google Scholar 

  43. Pendlebury SC, Cahill S, Crandon AJ, et al. Role of bipedal lymphangiogram in radiation treatment planning for cervix cancer. Int J Radiat Oncol Biol Phys 1993;27:959–962.

    PubMed  CAS  Google Scholar 

  44. Scheidler J, Hrick H, Yu KK, et al. Radiological evaluation of lymph node metastases in patients with cervical cancer. A meta-analysis. JAMA 1997;278:1096–1101.

    Article  PubMed  CAS  Google Scholar 

  45. Heller PB, Malfetano JH, Bundy BN, et al. Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix. Extended diagnostic evaluation for paraaortic node metastasis: a Gynecologic Oncology Group study. Gynecol Oncol 1990;38:425–430.

    Article  PubMed  CAS  Google Scholar 

  46. Kim SH, Kim SC, Choi BI, Han MC. Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging. Radiology 1994;190:807–811.

    PubMed  CAS  Google Scholar 

  47. Kim SH, Choi BI, Han JK, Kim HD, Lee HP, Kang SB, et al. Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. J Comput Assist Tomogr 1993;17(4):633–640.

    PubMed  CAS  Google Scholar 

  48. Hawighorst H, Schoenberg SO, Knapstein PG, Knopp MV, Schaeffer U, Essig M, van Kaick G. Staging of invasive cervical carcinoma and of pelvic lymph nodes by high resolution MRI with a phased-array coil in comparison with pathological findings. J Comput Assist Tomogr 1998;22:75–81.

    Article  PubMed  CAS  Google Scholar 

  49. Rose PG, Adler LP, Rodriguez M, et al. PET for evaluating paraaortic nodal metastases in locally advanced cervical cancer before surgical staging: a surgicopathological study. J Clin Oncol 1999;17:41–45.

    PubMed  CAS  Google Scholar 

  50. Reinhardt MJ, Ehritt-Braun C, Vogelgesang D, et al. Metastatic lymph nodes in patients with cervical cancer; detection with MR imaging and FDG-PET. Radiology 2001;218:776–782.

    PubMed  CAS  Google Scholar 

  51. Yeh LS, Hung YC, Shen YY, Kao CH, Lin CC, Lee CC. Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings. Oncol Rep 2002;9:1289–1292.

    PubMed  Google Scholar 

  52. Lin WC, Hung YC, Yeh LS, Kao CH, Yen RF, Shen YY. Usefulness of (18)-F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical carcinoma with negative computed tomography findings. Gynecol Oncol 2003;89:73–76.

    Article  PubMed  Google Scholar 

  53. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999;40:1125–1131.

    PubMed  CAS  Google Scholar 

  54. Narayan K, Hicks RJ, Jobling T, Bernshaw D, McKenzie AF. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer 2001;11:263–271.

    Article  PubMed  CAS  Google Scholar 

  55. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys 2003;53:353–359.

    Article  Google Scholar 

  56. Esthappan J, Mutic S, Malyapa RS, et al. Treatment planning guidelines regarding the use of CT/PET guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys 2004;58:1289–1297.

    Article  PubMed  Google Scholar 

  57. Mutic S, Malyapa RS, Grigsby PW, et al. PET-guided IMRT for cervical carcinoma with positive para-aortic nodes: a dose escalation treatment planning strategy. Int J Radiat Oncol Biol Phys 2003;56:489–493.

    Article  Google Scholar 

  58. Miller TR, Pinkus E, Dehdashti F, Grigsby PW. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med 2003;44(2):192–197.

    PubMed  Google Scholar 

  59. Singh AK, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. FDGPET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003;56(2):489–493.

    Article  PubMed  Google Scholar 

  60. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004;22:2167–2171.

    Article  PubMed  Google Scholar 

  61. Leisure GP, Vesselle HJ, Faulhaber PF, et al. Technical improvements in fluorine-18-FDG PET imaging of the abdomen and pelvis. J Nucl Med Technol 1997;25:115–119.

    PubMed  CAS  Google Scholar 

  62. Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol 2004;94:212–216.

    Article  PubMed  Google Scholar 

  63. Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003;44:347–352.

    PubMed  Google Scholar 

  64. Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003;90:186–190.

    Article  PubMed  Google Scholar 

  65. Lai Ch, Huang KG, See LC, et al. Restaging of recurrent cervical carcinoma with dual-phase [18F]-fluoro-2-deoxy-D-glucose positron emission tomography. Cancer (Phila) 2004;100:544–552.

    Article  PubMed  Google Scholar 

  66. Yen T-C, See L-C, Chang T-C, et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004;45:1632–1638.

    PubMed  Google Scholar 

  67. Ma SY, See LC, Lai CH, et al. Delayed (18)F FDG PET for the detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2004;44:1775–1783.

    Google Scholar 

  68. Lapela ML, Leskinen-Kallio S, Varpula M, et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J Nucl Med 1994;35:1618–1623.

    PubMed  CAS  Google Scholar 

  69. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550–1559.

    Article  PubMed  CAS  Google Scholar 

  70. Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecological Oncology Group experience. J Clin Oncol 1991;9:1138–1150.

    PubMed  CAS  Google Scholar 

  71. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989;4:1–12.

    PubMed  CAS  Google Scholar 

  72. Outwater EK, Dunton CJ. Imaging of ovary and adnexa: clinical issues and applications of MR imaging. Radiology 1995;194:1–18.

    PubMed  CAS  Google Scholar 

  73. Warde P, Ridenour DF, Herman S. Computed tomography in advanced ovarian cancer: inter-and intraobserver reliability. Invest Radiol 1986;21:31–33.

    Article  PubMed  CAS  Google Scholar 

  74. Buy J-N, Ghossian MA, Schiot C, Bazot M, et al. Epithelial tumours of the ovary: CT findings and correlation with US. Radiology 1991;178:811–818.

    PubMed  CAS  Google Scholar 

  75. Nelson BE, Rosenfield A, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993:166–172.

    Google Scholar 

  76. Lund B, Jacobsen K, Rasch I. Correlation of abdominal ultrasound and computed tomography scans with second or third look laparotomy in patients with ovarian carcinoma. Gynecol Oncol 1990;37:279–283.

    Article  PubMed  CAS  Google Scholar 

  77. Pestasides D, Kayianni H, Facou A, et al. Correlation of abdominal computed tomography scanning and second-look operation findings in with ovarian cancer patients Am J Clin Oncol 1991;14:457–462.

    Article  Google Scholar 

  78. Schroder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. Int J Gynecol Cancer 1999;9:117–122.

    Article  PubMed  Google Scholar 

  79. Grab D, Flock F, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging and positron emission tomography. Gynecol Oncol 2000;77:454–459.

    Article  PubMed  CAS  Google Scholar 

  80. Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre-and postmenopausal patients: assessment by PET/CT. J Nucl Med 2004;45:266–271.

    PubMed  Google Scholar 

  81. Lapela ML, Leskinen-Kallio S, Varpula M, et al. Metabolic imaging of ovarian tumours with carbon-11-methionine: A PET study. J Nucl Med 1995;36:2196–2200.

    PubMed  CAS  Google Scholar 

  82. Reiber A, Nussle K, Stohr I, et al. Preoperative diagnosis of ovarian tumours with MR imaging: comparison with transvaginal sonography, positron emission tomography and histological findings. Am J Roentgenol 2001;177:123–129.

    Google Scholar 

  83. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathological findings. Radiology 2002 223:780–788.

    PubMed  Google Scholar 

  84. Kawahara K, Yoshida Y, Kurokawa T, et al. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr 2004;28:505–516.

    Article  PubMed  Google Scholar 

  85. Yoshida Y, Kurokawa T, Kawahara T, et al. Incremental benefit of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Am J Roentgenol 2004;182:227–233.

    Google Scholar 

  86. Zimny M, Siggelkow W, Schroder W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gyncol Oncol 2001;83:310–315.

    Article  CAS  Google Scholar 

  87. Torizuka T, Nobezawa S, Kanno T, et al. Ovarian cancer recurrence: role of whole body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur J Nucl Med Mol Imaging 2002;29:797–803

    Article  PubMed  CAS  Google Scholar 

  88. Jimenez-Bonilla J, Maldonado A, Morales S, et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumour serum marker levels. Clin Posit Imaging 2000;3:231–236.

    Article  Google Scholar 

  89. Yen RF, Sun SS, Shen YY, Changlai SP, Kap A. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res 2001;21:3691–3694.

    PubMed  CAS  Google Scholar 

  90. Nakamoto Y, Saga T, Ishimori T, et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. Am J Roentgenol 2001;176:1449–1454.

    CAS  Google Scholar 

  91. Valk PE, Abella-Columna E, Haseman MK, et al. Whole-body PET imaging with [18F]fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503–511.

    Article  PubMed  CAS  Google Scholar 

  92. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol Oncol 2002;85:53–58

    Article  PubMed  CAS  Google Scholar 

  93. Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreduction surgery using combined PET/CT. Gynecol Oncol 2003;90:519–528.

    Article  PubMed  Google Scholar 

  94. Pannu HK, Cohade C, Bristow RE, Fishman EK, Wahl L. PET/CT detection of abdominal recurrence of ovarian cancer: radiologicsurgical correlation. Abdom Imaging 2004;29:398–403.

    Article  PubMed  CAS  Google Scholar 

  95. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol 2001;82:17–21.

    Article  PubMed  CAS  Google Scholar 

  96. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med 2003;44:1407–1412.

    PubMed  Google Scholar 

  97. Kim S, Chung JK, Kang SB, et al. [18F]FDG PET as a substitute for second look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging 2004;31:196–201.

    Article  PubMed  Google Scholar 

  98. Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Posit Imaging 1999;2:63–70.

    Article  Google Scholar 

  99. Belochine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of (18)F-FDG-PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging 2002;29:1132–1139.

    Article  CAS  Google Scholar 

  100. Saga T, Higashi T, Ishimori T, et al. Clinical value of FDG-PET in the follow up of postoperative patients with endometrial cancer. Ann Nucl Med 2003;17:197–303.

    Article  PubMed  Google Scholar 

  101. Lapela ML, Leskinen-Kallio S, Varpula M, et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J Nucl Med 1994;35:1618–1623.

    PubMed  CAS  Google Scholar 

  102. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol 2001;80(3):372–377.

    Article  PubMed  CAS  Google Scholar 

  103. Cohn DE, Dehdashti F, Gibb RK, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol 2002;85:179–184.

    Article  PubMed  Google Scholar 

  104. Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol 2001;19:2674–2678.

    PubMed  CAS  Google Scholar 

  105. Hyde NC, Prvulovich E, Newman L, Waddington WA, Visirkis D, Ell P. A new approach to pre-treatment assessment of the N0 neck in oral squamous cell carcinoma: the role of sentinel node biopsy and positron emission tomography. Oral Oncol 2003;39:350–360.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Nuclear Medicine Middlesex Hospital, UCH NHS Trust and Hammersmith Hospitals NHS Trust, London, UK

    Sharon F. Hain BSc, MBBS, FRACP

Authors
  1. Sharon F. Hain BSc, MBBS, FRACP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Northern California PET Imaging Center, Sacramento, CA, USA

    Peter E. Valk MB, BS, FRACP

  2. Positron Emission Tomography, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA

    Dominique Delbeke MD, PhD (Professor and Director of Nuclear Medicine) (Professor and Director of Nuclear Medicine)

  3. Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia

    Dale L. Bailey PhD (Associate Professor of Medicine) (Associate Professor of Medicine)

  4. Cancer Imaging and Tracer Development Program, The University of Tennessee Medical Center, Knoxville, TN, USA

    David W. Townsend PhD (Director) (Director)

  5. Department of Radiological Sciences, Guy’s and St Thomas’ Clinical PET Centre, Guy’s and St Thomas’ Hospital Trust, London, UK

    Michael N. Maisey BSc, MD, FRCR, FRCP (Professor of Emeritus) (Professor of Emeritus)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag London Limited

About this chapter

Cite this chapter

Hain, S.F. (2006). PET and PET/CT Imaging in Testicular and Gynecologic Cancers. In: Valk, P.E., Delbeke, D., Bailey, D.L., Townsend, D.W., Maisey, M.N. (eds) Positron Emission Tomography. Springer, London . https://doi.org/10.1007/1-84628-187-3_14

Download citation

  • DOI: https://doi.org/10.1007/1-84628-187-3_14

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-971-5

  • Online ISBN: 978-1-84628-187-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation